C4 Therapeutics presents new biomarker data from cemsidomide trials
C4 Therapeutics said it presented new biomarker data from its phase 1 cemsidomide trial with dexamethasone and phase 1b trial with elranatamab at the IMS annual meeting.
C4 Therapeutics said it presented new biomarker data from its phase 1 cemsidomide trial with dexamethasone and phase 1b trial with elranatamab at the IMS annual meeting.